经腹与腔内超声联合检查与增强CT在胃肠间质瘤分子靶向药物疗效评估中的对比研究

Comparative study of combined transabdominal and intraluminal ultrasound and enhancement CT on evaluating the treatment effectiveness of molecularly targeted drugs for gastrointestinal stromal tumors

目的:探讨经腹与腔内超声联合检查在胃肠间质瘤分子靶向药物疗效评估中的价值。方法:回顾性分析35例经病理证实并行分子靶向药物治疗的胃肠间质瘤患者的超声及增强CT检查资料,以实体瘤疗效反应的评价标准(the response evaluation criteria in solid tumors,RECIST)作为评估标准,比较2种影像检查方法评估药物疗效的一致性。结果:超声与增强CT 2种检查方法在胃肠间质瘤分子靶向药物疗效评估中的结果一致性满意,Kappa值为0.821 (P<0.001),2种检查的评估结果差异无统计学意义(P>0.05)。结论:超声在评价胃肠间质瘤分子靶向药物疗效方面与增强CT具有一致性,可作为评估胃肠间质瘤分子靶向药物疗效一种影像检查方法。

Objective:To investigate the value of combined trans-abdominal and intraluminal ultrasound on evaluating treatment effectiveness of molecularly targeted drugs in gastrointestinal stromal tumors(GIST). Methods:A total of 35 patients with GIST confirmed by pathology and immunohistochemistry,who treated with molecularly targeted drugs,were enrolled in this study and their clinical and image data of evaluating the treatment response of targeted drug therapy using both ultrasound and CECT were collected and retrospectively analyzed. According to the response evaluation criteria in solid tumors(RECIST),the coincidence rate and consistency of two imaging methods in evaluating the treatment response of drugs for GIST patients were compared. Results:The consistency of evaluation results of GSIT by two methods of ultrasound and enhanced CT was satisfactory. The Kappa value was 0.821(P<0.001). There was no significant difference in evaluation of treatment effectiveness of two imaging methods(P>0.05). Conclusion:Ultrasound is consistent with enhancement CT for evaluating molecularly targeted drugs in GSIT,which can be an imaging examination method.